We believe that sickness has no boundaries, and compassion has no limits.

The KIS Foundation, Inc. is dedicated to improving the social health and quality of life for patients and families living with Sickle Cell Disease. We are firm believers that individuals and groups should not simply wait for SCD to affect them personally before getting involved and making a difference. This proactive outlook combined with a community service-based infrastructure has made The KIS Foundation, Inc a successful non-profit organization for over 17 years.

Click Here To Purchase Sponsorships / Teams / Individual Golfing Spots

KiKi Shepard's 6th Annual "Celebrity Golf Classic" hosted by LA Lakers Legend Byron Scott, will be held on Monday, September 9, 2024, benefiting The K I S Foundation, Inc. You’re Invited to join us as we return to the stunning Porter Valley Country Club, in Los Angeles, California. This amazing event strives to educate the public about Sickle Cell Disease (SCD), how it is spread, its debilitating and deadly effects, ways of prevention, yearly hands-on support of this deserving community, and the need to get tested now!

bigstock-Black-Family-on-a-beach-27384848.jpg

Learn about Sickle cell disease

Take time to familiarize and learn about the details and history behind Sickle Cell Disease.

A letter from
Our founder

Read a letter from our Founder KiKi Shepard,  describing her passions and experiences with SCD.

Lima01.jpg

Ways for you to
Get involved

There are multiple ways that you can get involved and make a difference in the SCD community.

Raise Awareness

Make A Difference

Quick Downloads & Resources

Here, you can find quick button links to important downloads and resources from The KIS Foundation.

Upcoming KIS Events

Here is a quick look at some of the upcoming events The KIS Foundation, Inc. has lined up in the near future.

Sickle Cell Disease: In The News

Our mission is to raise awareness, advocate and educate, and to remain current with SCD news in the community.

Sickle Cell: In The News
SCDAA Statement About Gene Therapy Approval
SCDAA Statement About Gene Therapy Approval

According to Sickle Cell Disease Association of America, SCDAA

“On Dec. 8, 2023, the Food and Drug Administration (FDA) approved two cell-based gene therapies for sickle cell disease (SCD), Casgevy from CRISPR/Vertex and Lyfgenia from bluebird bio. These are the first treatments of their kind available to individuals with SCD in the United States. SCDAA welcomes the approval of these potentially curative therapies which mark major advances in the treatment of sickle cell disease; however, there are valid concerns about accessibility and the potential for adverse effects.”

Biden-Harris Administration Announces Action to Increase Access to Sickle Cell Disease Treatments
Biden-Harris Administration Announces Action to Increase Access to Sickle Cell Disease Treatments

According to Sickle Cell Disease Association of America, CMS.gov press release

“The Biden-Harris Administration announced today that sickle cell disease (SCD) will be the first focus of the Cell and Gene Therapy (CGT) Access Model, which was initially announced in February 2023. The model is designed to improve health outcomes, increase access to cell and gene therapies, and lower health care costs for some of the nation’s most vulnerable populations.”

CMMI Announces the Cell and Gene Therapy Access Model
CMMI Announces the Cell and Gene Therapy Access Model

According to Sickle Cell Disease Association of America, SCDAA

“Today, the Centers for Medicare and Medicaid Innovation (CMMI) announced the launch of their new Cell and Gene Therapy Access Model, a demonstration aimed at improving access to cell and gene therapy products in the Medicaid program. CMMI chose sickle cell disease (SCD) as the first indication for the model. The intent of the model is to provide access to the two recently approved gene therapy products for SCD for individuals insured by Medicaid. Participation by state Medicaid programs will be optional.”